Checkpoint Therapeutics, Inc. is a commercial-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Its product candidates include UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic cSCC or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Additionally, the Company is engaged in evaluating its lead investigational small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Closed - Nasdaq 00:00:00 30/05/2025 +04			5-day change	1st Jan Change
4.260 ^USD	+0.71%		-.--%	-

02/06/25	Checkpoint Therapeutics, Inc.(NasdaqCM:CKPT) dropped from S&P TMI Index	CI
30/05/25	Sun Pharmaceutical Industries Limited completed the acquisition of Checkpoint Therapeutics, Inc. from Fortress Biotech, Inc., Armistice Capital Master Fund Ltd., managed by Armistice Capital LLC and others.	CI

Market Cap	371M 323M 305M 277M 519M 35.57B 521M 3.66B 1.41B 18.08B 1.39B 1.36B 58.19B	P/E 2023	-1.23x	P/E 2024	-2.26x
Enterprise Value	364M 317M 300M 272M 510M 34.94B 512M 3.59B 1.39B 17.76B 1.37B 1.34B 57.15B	EV / Sales 2023	475x	EV / Sales 2024	3,650x
Free-Float	47.41%	Yield 2023 *	-	Yield 2024	-

02/06/25	Checkpoint Therapeutics, Inc.(NasdaqCM:CKPT) dropped from S&P TMI Index	CI
30/05/25	Sun Pharmaceutical Industries Limited completed the acquisition of Checkpoint Therapeutics, Inc. from Fortress Biotech, Inc., Armistice Capital Master Fund Ltd., managed by Armistice Capital LLC and others.	CI
30/05/25	Sun Pharmaceutical Industries Completes Acquisition Of Checkpoint Therapeutics	RE
30/05/25	Fortress Biotech Closes Sale of Checkpoint Therapeutics Unit	MT
30/05/25	Checkpoint Therapeutics, Inc. Appoints Zvi Albert as Chief Financial Officer	CI
30/05/25	Checkpoint Therapeutics, Inc. Announces Board and Executive Changes	CI
30/05/25	Checkpoint Therapeutics, Inc.(NasdaqGM:CKPT) dropped from NASDAQ Composite Index	CI
14/05/25	Checkpoint Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
28/03/25	Checkpoint Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
28/03/25	Checkpoint Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
11/03/25	HC Wainwright Downgrades Checkpoint Therapeutics to Neutral From Buy, $20 Price Target	MT
10/03/25	Lake Street Downgrades Checkpoint Therapeutics to Hold From Buy, $4.10 Price Target	MT
10/03/25	Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical -- Checkpoint Shares Jump Monday	MT

11/03/25	HC Wainwright Downgrades Checkpoint Therapeutics to Neutral From Buy, $20 Price Target	MT
10/03/25	Lake Street Downgrades Checkpoint Therapeutics to Hold From Buy, $4.10 Price Target	MT
20/12/23	B. Riley Lowers Checkpoint Therapeutics' Price Target to $4 From $8, Keeps Buy Rating	MT
22/08/23	B. Riley Lowers Checkpoint Therapeutics' Price Target to $8 From $15, Keeps Buy Rating	MT
15/08/23	Lake Street Adjusts Checkpoint Therapeutics Price Target to $14 From $16, Maintains Buy Rating	MT

Checkpoint Therapeutics, Inc. Stock

Stocks

CKPT

US1628282063

Biotechnology & Medical Research

Valuation: Checkpoint Therapeutics, Inc.

Latest news: Checkpoint Therapeutics, Inc.

Analysts' recommendations: Checkpoint Therapeutics, Inc.

Press Releases: Checkpoint Therapeutics, Inc.

News in other languages: Checkpoint Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Checkpoint Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

30/05/25	Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics	AQ
14/05/25	Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates	AQ
29/04/25	CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT	BU
28/03/25	Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates	AQ
14/03/25	CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT	BU

22/08/24	Avery Dennison Corporation : Todo lo que busca
18/07/24	Zscaler, Inc.: de kunst van de Zero Trust-aanpak
17/07/24	Zscaler: l'arte dell'approccio zero trust
16/07/24	Zscaler, Inc.: El arte del enfoque de confianza cero
16/07/24	Zscaler : l'art de l'approche zero trust

Date	Insider	Type	Main position	Quantity	% Market Cap.
30/05/25	James Oliviero	Tender	Chief Executive Officer	3,759,929	7.8116%
30/05/25	William Gray	Tender	Chief Financial Officer	1,446,322	3.0049%
29/05/25	FORTRESS BIOTECH, INC.	Issuer sale	Company	700,000	7.5395%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHECKPOINT THERAPEUTICS, INC.	+0.71%	-.--%	-.--%	+129.03%	357M
WUXI APPTEC CO., LTD.	-0.31%	+5.79%	+48.93%	+97.53%	70.88B
ARGENX SE	+0.39%	+2.06%	+40.91%	+78.49%	62.49B
INSMED INCORPORATED	-3.21%	-7.27%	-17.73%	+351.98%	26.21B
WUXI BIOLOGICS (CAYMAN) INC.	+0.50%	+7.13%	+29.43%	+15.48%	26.34B
BIONTECH SE	-2.64%	-0.69%	-0.26%	-11.90%	24.13B
GENMAB A/S	+0.71%	+8.03%	+27.22%	-13.18%	20.72B
PHARMAESSENTIA CORPORATION	-1.26%	-7.81%	+169.33%	+302.38%	15.36B
EXELIXIS, INC.	-0.22%	+3.99%	+44.28%	+173.35%	14.46B
SUMMIT THERAPEUTICS INC.	+0.73%	+1.71%	-7.18%	+886.19%	14.25B
Average	-0.46%	+1.48%	+33.49%	+200.93%	27.52B
Weighted average by Cap.	-0.47%	+1.44%	+36.46%	+147.95%

	2023	2024
Net sales	103K 89.82K 84.81K 77.01K 144K 9.88M 145K 1.02M 392K 5.02M 387K 378K 16.17M	41K 35.75K 33.76K 30.65K 57.43K 3.93M 57.67K 404K 156K 2M 154K 151K 6.44M
Net income	-51.85M -45.21M -42.69M -38.76M -72.63M -4.97B -72.93M -511M -197M -2.53B -195M -190M -8.14B	-56.24M -49.04M -46.31M -42.05M -78.78M -5.4B -79.11M -555M -214M -2.74B -211M -207M -8.83B
Net Debt	-4.93M -4.3M -4.06M -3.68M -6.9M -473M -6.93M -48.6M -18.76M -240M -18.51M -18.1M -774M	-6.6M -5.76M -5.44M -4.94M -9.25M -634M -9.29M -65.13M -25.13M -322M -24.81M -24.26M -1.04B

3 years	1.3	4.5
5 years	1.3	46.4
10 years	1.3	150